BeiGene(BGNE)
China - BeijingBiotechnology
Focus: BeiGene is a publicly-traded Chinese biotechnology company with 10,001+ employees focused on developing oncology therapies for global markets. It maintains a robust pipeline of 30+ programs spanning multiple cancer indications.
Profile data last refreshed 19h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Employees
10001+
Open Jobs
304+122 this month
Hot — 242 jobs added in 30d
Net +122 (242 new, 120 removed). Aggressive expansion phase.
Should You Work at BeiGene?
AI assessmentStrong fit for commercial, medical affairs, and regulatory professionals seeking exposure to late-stage oncology assets; higher uncertainty for R&D-focused scientists due to limited pipeline and financial visibility.
Why Work Here
- Access to a late-stage pipeline with 4 Phase 3 programs (zanubrutinib, tislelizumab, ociperlimab, sitravatinib) providing near-term catalysts and commercial visibility
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
First line therapy
CLL/SLLPhase 1
Clinical Trials (1)
Help build intelligence for BeiGene
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.